Data Foundry

Drug recalls 2025

Carvedilol Tablets — Class II drug recall D-0577-2025

Ongoing recall by Glenmark Pharmaceuticals Inc., USA, reported 2025-08-20, distributed nationwide. CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intak

Recall numberD-0577-2025
Product typeDrug
ClassificationClass II
StatusOngoing
Voluntary or mandatedVoluntary
Recalling firmGlenmark Pharmaceuticals Inc., USA, Mahwah, NJ, United States
Recall initiated2025-08-07
Classified2025-08-12
Reported by FDA2025-08-20
DistributedNationwide (US)
Quantity44,328 bottles
Reason classeschemical contamination, cgmp, specification failure
NDC68462-0162, 68462-0162-01, 68462-0162-05, 68462-0162-10, 68462-0162-18, 68462-0162-60, 68462-0163, 68462-0163-01, 68462-0163-05, 68462-0163-10, 68462-0163-18, 68462-0163-60, 68462-0164, 68462-0164-01, 68462-0164-05, 68462-0164-10, 68462-0164-18, 68462-0164-60, 68462-0165, 68462-0165-01, 68462-0165-05, 68462-0165-10, 68462-0165-18, 68462-0165-60
Expiration dates2020-05-31, 2026-05-31

Product

Carvedilol Tablets, USP, 3.125 mg, Packaged as: a)500-count bottle, NDC 68462-162-05; b) 100-count bottle, NDC 68462-162-01; Rx only, Manufactured by: Glenmark Pharmaceuticals Ltd, Colvale-Bardez, Goa, 403513, India. Manufactured for Glenmark Pharmaceuticals, Inc., Mahwah, NJ, USA, NJ 07430.

Reason for recall

CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0577-2025. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.